Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Chattem, Inc. ("Chattem" or the "Company") (NASDAQ:CHTT) arising from the Company’s announcement of its intent to be acquired by Sanofi-aventis (“Sanofi”). Under the terms of the proposed transaction, Chattem shareholders will receive $93.50 in cash for each Chattem share owned in a transaction with a total value of $1.9 billion. The investigation is focused on the potential unfairness of the price to Chattem shareholders and the process by which the Company’s Board of Directors considered and approved the transaction.

If you are interested in discussing your rights as a Chattem shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, D.C. offices at (877) 337-1050 or by email at This email address is being protected from spam bots, you need Javascript enabled to view it .